Gilead: Remdesivir reduces COVID-19 hospitalization risk


Patients' risk of hospitalization or all-cause mortality decreased 87% with a three-day course of intravenous remdesivir, according to data released by Gilead. Remdesivir is approved for use in hospitalized patients, but outpatient treatment for high-risk individuals like those included in the study is investigational.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.